Skip navigation
Home
Browse
Communities
& Collections
Browse Items by:
Issue Date
Author
Title
Advisor
Help
Sign on to:
My DSpace
Receive email
updates
Edit Profile
Adelaide Research & Scholarship
Adelaide Research & Scholarship
Search
Search:
All collections
Schools and Disciplines
School of Medicine
Medicine
Medicine publications
for
Current filters:
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Start a new search
Add filters:
Use filters to refine the search results.
Title
Author
Subject
Date Issued
Advisor
School
Department
Organisation
Equals
Contains
ID
Not Equals
Not Contains
Not ID
Results 1-10 of 12 (Search time: 0.003 seconds).
previous
1
2
next
Item hits:
Preview
Issue Date
Title
Author(s)
2012
Contrasting effects of diclofenac and ibuprofen on active imatinib uptake into leukaemic cells
Wang, J.
;
Hughes, T.
;
Kok, C.
;
Saunders, V.
;
Frede, A.
;
Groot Obbink, K.
;
Osborn, M.
;
Somogyi, A.
;
D'Andrea, R.
;
White, D.
2012
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
Yin, O.
;
Giles, F.
;
Baccarani, M.
;
le Coutre, P.
;
Chiparus, O.
;
Gallagher, N.
;
Saglio, G.
;
Hughes, T.
;
Hochhaus, A.
;
Kantarjian, H.
;
Larson, R.
2012
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph plus chronic myeloid leukemia in chronic phase
Larson, R.
;
Yin, O.
;
Hochhaus, A.
;
Saglio, G.
;
Clark, R.
;
Nakamae, H.
;
Gallagher, N.
;
Demirhan, E.
;
Hughes, T.
;
Kantarjian, H.
;
le Coutre, P.
2012
Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A
Blake, S.
;
Hughes, T.
;
Lyons, A.
2012
Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up
Larson, R.
;
Hochhaus, A.
;
Hughes, T.
;
Clark, R.
;
Etienne, G.
;
Kim, D.
;
Flinn, I.
;
Kurokawa, M.
;
Moiraghi, B.
;
Yu, R.
;
Blakesley, R.
;
Gallagher, N.
;
Saglio, G.
;
Kantarjian, H.
2012
Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors
Nieborowska-Skorska, M.
;
Kopinski, P.
;
Ray, R.
;
Hoser, G.
;
Ngaba, D.
;
Flis, S.
;
Cramer, K.
;
Reddy, M.
;
Koptyra, M.
;
Penserga, T.
;
Glodkowska-Mrowka, E.
;
Bolton, E.
;
Holyoake, T.
;
Eaves, C.
;
Cerny-Reiterer, S.
;
Valent, P.
;
Hochhaus, A.
;
Hughes, T.
;
Van der Kuip, H.
;
Sattler, M.
;
et al.
2012
BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management
Branford, S.
;
Yeung, D.
;
Prime, J.
;
Choi, S.
;
Bang, J.
;
Park, J.
;
Kim, D.
;
Ross, D.
;
Hughes, T.
2012
Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response
White, D.
;
Hughes, T.
2012
Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia
Yeung, D.
;
Hughes, T.
2012
Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial
Guilhot, F.
;
Hughes, T.
;
Cortes, J.
;
Druker, B.
;
Baccarani, M.
;
Gathmann, I.
;
Hayes, M.
;
Granvil, C.
;
Wang, Y.
Discover
Author
5
Saglio, G.
4
Hochhaus, A.
4
Kantarjian, H.
3
Gallagher, N.
3
Kim, D.
3
Larson, R.
3
White, D.
2
Baccarani, M.
2
Clark, R.
2
Frede, A.
.
next >
Subject
5
Humans
4
Fusion Proteins, bcr-abl
4
imatinib
3
Chronic myeloid leukemia
3
Leukemia, Myeloid, Chronic-Phase
3
Piperazines
3
Protein Kinase Inhibitors
3
Pyrimidines
2
Animals
2
Antineoplastic Agents
.
next >